APB-B002

APB-B002 is a bispecific monoclonal antibody currently in the discovery and preclinical stage of development by APITBIO for the treatment of solid cancers. It is designed to simultaneously target CD171 (also known as L1 cell adhesion molecule or L1CAM) and a second, currently undisclosed target. CD171 is a transmembrane glycoprotein that is frequently overexpressed in various aggressive malignant tumors, where it is associated with poor prognosis and plays a key role in promoting tumor cell migration, invasion, and resistance to chemotherapy. By utilizing a bispecific format, APB-B002 aims to achieve enhanced anti-tumor efficacy through dual-pathway inhibition or by increasing tumor specificity compared to monospecific therapies.